Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

[1]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[2]  C. Janeway,et al.  Maintenance of TCR clonality in T cells expressing genes for two TCR heterodimers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Nolan,et al.  Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. , 2001, Clinical immunology.

[4]  T N Schumacher,et al.  Changing T cell specificity by retroviral T cell receptor display. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Hans-Georg Rammensee,et al.  Two new proteases in the MHC class I processing pathway , 2000, Nature Immunology.

[6]  J. Foote,et al.  Breaking the affinity ceiling for antibodies and T cell receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Kalos,et al.  Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes , 2000, Journal of Virology.

[8]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[9]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[10]  K D Wittrup,et al.  In vitro evolution of a T cell receptor with high affinity for peptide/MHC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Hipp,et al.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Kloetzel,et al.  Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes , 2000, The Journal of experimental medicine.

[13]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[14]  C. Huber,et al.  Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. , 1999, Cancer research.

[15]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[16]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[17]  H. Stauss,et al.  Immunotherapy with CTLs restricted by nonself MHC. , 1999, Immunology today.

[18]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[19]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[20]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[21]  H. Rammensee,et al.  Alloreactivity as a source of high avidity peptide-specific human CTL. , 1999, Journal of immunology.

[22]  A. Levine,et al.  Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. , 1999, Cancer research.

[23]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[24]  A. Levine,et al.  Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein , 1998, The EMBO journal.

[25]  H. Stauss,et al.  Generation of human tumor‐reactive cytotoxic T cells against peptides presented by non‐self HLA class I molecules , 1998, European journal of immunology.

[26]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.

[27]  A. Goldberg,et al.  Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Bevan,et al.  In thymic selection, peptide diversity gives and takes away. , 1997, Immunity.

[29]  P. Kloetzel,et al.  Molecular cloning of the mouse proteasome subunits MC14 and MECL‐1: reciprocally regulated tissue expression of interferon‐γ‐modulated proteasome subunits , 1997, European journal of immunology.

[30]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[31]  M. Theobald,et al.  Tolerance to p 53 by A 2 . 1-restricted Cytotoxic T Lymphocytes , 1997 .

[32]  E. Sadovnikova,et al.  Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Hans-Georg Rammensee,et al.  Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands , 1996, Cell.

[34]  A. Levine,et al.  Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Kawasaki,et al.  A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[37]  P. S. Kim,et al.  Peptide ‘Velcro’: Design of a heterodimeric coiled coil , 1993, Current Biology.

[38]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.

[39]  L. Sherman,et al.  Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. , 1992, Science.

[40]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[41]  H. Rammensee,et al.  On the nature of peptides involved in T cell alloreactivity , 1991, The Journal of experimental medicine.

[42]  H. Pircher,et al.  Lower receptor avidity required for thymic clonal deletion than for effector T-cell function , 1991, Nature.

[43]  C. Janeway,et al.  Ligand thresholds at different stages of T cell development. , 1990, International immunology.

[44]  H. Rammensee,et al.  Evidence from in vitro studies that tolerance to self antigens is MHC-restricted , 1984, Nature.

[45]  P. Matzinger,et al.  Is self tolerance H–2 restricted? , 1980, Nature.